MX2009004984A - Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina. - Google Patents

Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.

Info

Publication number
MX2009004984A
MX2009004984A MX2009004984A MX2009004984A MX2009004984A MX 2009004984 A MX2009004984 A MX 2009004984A MX 2009004984 A MX2009004984 A MX 2009004984A MX 2009004984 A MX2009004984 A MX 2009004984A MX 2009004984 A MX2009004984 A MX 2009004984A
Authority
MX
Mexico
Prior art keywords
methods
renal function
xanthine oxidoreductase
preserving renal
oxidoreductase inhibitors
Prior art date
Application number
MX2009004984A
Other languages
English (en)
Inventor
Christopher Lademacher
Patricia Macdonald
Original Assignee
Takeda Pharmaceuticals North A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals North A filed Critical Takeda Pharmaceuticals North A
Publication of MX2009004984A publication Critical patent/MX2009004984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención se refiere a métodos para conservar la función renal en un sujeto que necesita de ello administrándole una cantidad efectiva terapéuticamente de al menos un compuesto inhibidor de xantina óxido reductasa o una sal de él.
MX2009004984A 2006-11-13 2007-11-13 Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina. MX2009004984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85850906P 2006-11-13 2006-11-13
PCT/US2007/084573 WO2008064015A1 (en) 2006-11-13 2007-11-13 Methods for preserving renal function using xanthine oxidoreductase inhibitors

Publications (1)

Publication Number Publication Date
MX2009004984A true MX2009004984A (es) 2009-09-23

Family

ID=39430048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004984A MX2009004984A (es) 2006-11-13 2007-11-13 Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.

Country Status (11)

Country Link
US (1) US20080269226A1 (es)
EP (1) EP2101761A4 (es)
JP (3) JP2010509372A (es)
KR (3) KR20160031040A (es)
CN (1) CN101677999A (es)
AU (1) AU2007323919A1 (es)
BR (1) BRPI0718611A2 (es)
CA (1) CA2669935A1 (es)
MX (1) MX2009004984A (es)
RU (1) RU2508099C2 (es)
WO (1) WO2008064015A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841333B2 (en) * 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
CA2675443A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals North America, Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
RU2602188C2 (ru) * 2010-06-16 2016-11-10 Такеда Фармасьютикалз Ю.Эс.Эй.,Инк. Фармацевтическая композиция с модифицированным высвобождением, включающая фебуксостат
JPWO2011162390A1 (ja) * 2010-06-25 2013-08-22 帝人ファーマ株式会社 徐放性高血圧および腎機能障害治療剤
CN102372679A (zh) * 2010-08-27 2012-03-14 北京润德康医药技术有限公司 一种非布司他水溶性衍生物及其制备方法
RU2013109380A (ru) 2010-09-10 2014-10-20 Такеда Фармасьютикалс Ю.С.А.,Инк. Способ сопутствующей терапии с применением теофиллина и фебуксостата
JP5862897B2 (ja) * 2010-11-01 2016-02-16 株式会社三和化学研究所 腎機能障害の予防又は治療に用いる医薬
CN102757403B (zh) * 2011-04-27 2015-04-29 浙江九洲药业股份有限公司 一种非布索坦衍生物及其制备方法
TW201328692A (zh) * 2011-10-11 2013-07-16 Univ Osaka 脫髓鞘疾病之治療劑及預防劑
RU2014134845A (ru) 2012-01-27 2016-03-20 Тейдзин Фарма Лимитед Терапевтическое средство против диабета
KR20150073963A (ko) * 2012-10-23 2015-07-01 데이진 화-마 가부시키가이샤 종양 융해 증후군의 치료약 및 예방약
CN103265636B (zh) * 2013-05-23 2015-09-16 中国药科大学 一种具有降血糖作用的新型肽
CN104548066A (zh) * 2015-01-19 2015-04-29 中国药科大学 一种具有降血糖作用的新型肽的新用途
CN105294584A (zh) * 2015-11-30 2016-02-03 中国医科大学 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途
EP3417858B8 (en) 2016-02-19 2020-12-30 National University Corporation Tottori University Therapeutic or prophylactic drug for dementia
CN106279024B (zh) * 2016-07-19 2018-09-14 华南理工大学 一种黄嘌呤氧化还原酶抑制剂及其制备方法与应用
KR20230119303A (ko) * 2022-02-07 2023-08-16 (주)인드림헬스케어 높은 혈중 요산 농도를 갖는 대상체의 만성 신장 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079303A (en) * 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4296122A (en) * 1975-07-09 1981-10-20 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids
DE2727802A1 (de) * 1977-06-21 1979-04-19 Hoechst Ag Sulfamoyl-arylketone und verfahren zu ihrer herstellung
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4632930A (en) * 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JPH0366669A (ja) * 1989-08-03 1991-03-22 Shionogi & Co Ltd 複素環式化合物
DE122008000051I1 (de) * 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
US5358961A (en) * 1991-11-30 1994-10-25 Jin Ro Limited Pyrrolidine derivatives
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5770601A (en) * 1994-08-17 1998-06-23 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US6037344A (en) * 1994-08-17 2000-03-14 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US5514681A (en) * 1994-08-17 1996-05-07 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
AUPM835394A0 (en) * 1994-09-23 1994-10-13 King, Michael G. Dr. Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need
ATE270550T1 (de) * 1995-04-07 2004-07-15 Teijin Ltd Wirkstoff zum schutz für organ oder gewebe
ID21775A (id) * 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
US5965625A (en) * 1997-03-21 1999-10-12 King; Michael Glenn Compositions and methods for the control of smoking
EP1044002A4 (en) * 1997-11-07 2003-05-02 Univ Johns Hopkins METHODS FOR THE TREATMENT OF HEART CONTRACTILITY
TR200000458T1 (tr) * 1998-06-19 2000-10-23 Teijin Limited 2-(3-siyano-4-izobütiloksifenil)-4-Metil-5-tiazolkarboksilik asit ve bunun üretilmesi için yöntem.
US6281222B1 (en) * 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
JP2004517804A (ja) * 2000-06-28 2004-06-17 メルク・アンド・カンパニー・インコーポレーテッド 心臓血管病の治療法
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
CA2444347A1 (en) * 2001-04-18 2002-10-31 Genzyme Corporation Method for treating gout and binding uric acid
PL208260B1 (pl) * 2002-01-28 2011-04-29 Fuji Yakuhin Co Związki 1,2,4-triazolu, lek zawierający związek oraz zastosowanie związku
AU2003220909B2 (en) * 2002-03-28 2008-09-18 Teijin Limited Solid preparation containing single crystal form
US20060040945A1 (en) * 2002-05-17 2006-02-23 Merckle Gmbh Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US20040131676A1 (en) * 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
WO2006028342A1 (en) * 2004-09-06 2006-03-16 Biosynergen, Inc. A novel xanthine oxidase inhibitor and a pharmaceutical composition containing the same
WO2006055412A1 (en) * 2004-11-19 2006-05-26 Shiva Biomedical, Llc Methods of treating erythropoietin-resistance
US8841333B2 (en) * 2005-05-09 2014-09-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating nephrolithiasis
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
CA2675443A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals North America, Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
RU2013109380A (ru) * 2010-09-10 2014-10-20 Такеда Фармасьютикалс Ю.С.А.,Инк. Способ сопутствующей терапии с применением теофиллина и фебуксостата

Also Published As

Publication number Publication date
KR20150024919A (ko) 2015-03-09
BRPI0718611A2 (pt) 2014-02-25
KR20090103879A (ko) 2009-10-01
AU2007323919A1 (en) 2008-05-29
JP2016188231A (ja) 2016-11-04
RU2508099C2 (ru) 2014-02-27
JP2010509372A (ja) 2010-03-25
CN101677999A (zh) 2010-03-24
US20080269226A1 (en) 2008-10-30
JP2014012726A (ja) 2014-01-23
JP6233899B2 (ja) 2017-11-22
EP2101761A4 (en) 2010-01-27
RU2009122505A (ru) 2010-12-20
EP2101761A1 (en) 2009-09-23
WO2008064015A1 (en) 2008-05-29
KR20160031040A (ko) 2016-03-21
CA2669935A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
MX2009004984A (es) Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
MY183014A (en) Compounds for enzyme inhibition
MX2011010332A (es) Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
MX2009013625A (es) Compuestos de di (arilamino) arilo.
WO2008019395A3 (en) Compounds for improving learning and memory
WO2007019153A3 (en) Methods for treating hypertension
HK1131146A1 (en) Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
MY153243A (en) Compound for inhibiting mitotic progression
NO20091664L (no) Farmaoytiske preparater av HDAC-inhibitorer og chelaterbare metallforbindelser samt metall-HDAC-inhibitor-chelatkomplekser
TN2011000293A1 (en) Protein kinase inhibitors
EP1986652A4 (en) AMINOETETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1978804A4 (en) AMINOCYCLOHEXANES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR TREATING OR PREVENTING DIABETES
EP2019677A4 (en) AMINOETETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
TN2009000224A1 (en) Inhibitors of akt activity
MX339829B (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
ZA200807488B (en) Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
HK1115500A1 (en) Isoquinolines as igf-1r inhibitors
TW200742580A (en) Methods for treating nephrolithiasis
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
WO2007008502A3 (en) Inhibitors of checkpoint kinases
WO2007084135A3 (en) Inhibitors of checkpoint kinases

Legal Events

Date Code Title Description
HC Change of company name or juridical status